Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Trial to Assess the Efficacy and Safety of Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Addition to the Standard of Care (SOC) Compared SOC in the Treatment of Hospitalized With COVID-19 Patients Who Not Requiring the Mechanical Ventilation

NCT04762628 is registered in ClinicalTrials.gov with Saisei Pharma as lead sponsor.

NCT NCT04762628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04762628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Trial to Assess the Efficacy and Safety of Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Addition to the Standard of Care (SOC) Compared SOC in the Treatment of Hospitalized With COVID-19 Patients Who Not Requiring the Mechanical Ventilation
Lead sponsor
Saisei Pharma
Phase
Not applicable
Overall status
Completed
Start date
October 27, 2020
Completion date
August 6, 2021
Enrollment
600 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid19